R
Reverb Therapeutics
Bispecific antibodies redirecting endogenous cytokines for therapy
About Reverb Therapeutics
Reverb Therapeutics is a preclinical-stage biotechnology company developing bispecific antibodies to treat diseases by harnessing the body's own immune system. Founded in 2023 by CEO David de Graaf and Chief Scientific Officer Surjit Dixit, the Vancouver-based startup emerged from Amplitude Ventures' Pre-Amp venture studio program. The co-founders bring extensive experience in biologics discovery and development; de Graaf is a serial biopharma entrepreneur, while Dixit was instrumental in developing Zymeworks' Azymetric™ bispecific platform.
The company's core technology is the Amplify•R™ platform, which engineers bispecific antibodies to capture the body's naturally occurring cytokines and concentrate them at specific sites, such as tumors or areas of autoimmune activity. This approach is designed to amplify the immune system's natural signaling locally, avoiding the systemic toxicity, immunogenicity, and manufacturing complexities often associated with administering engineered, external (exogenous) cytokines. The platform combines antibody engineering with data-driven modeling and is modular, allowing for rapid pipeline development across various diseases.
Reverb's business model is focused on advancing its proprietary drug pipeline through preclinical and clinical development. Its initial therapeutic areas are cancer and autoimmune diseases. The lead program, AMP01, uses this technology to block a protein that suppresses immune response while delivering another that activates cancer-fighting T-cells. Preclinical in-vivo studies have demonstrated proof-of-concept, showing the platform's ability to shrink tumors by redirecting these internal cytokines. In February 2025, Reverb Therapeutics announced the closing of a $12 million USD seed financing round led by founding investor Amplitude Ventures, with participation from the Myeloma Investment Fund, KdT Ventures, Finchley Healthcare Ventures, and others, to advance its lead programs to the candidate stage.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Feb 2025 | $12M | $48M | KdT Ventures · Myeloma Investment Fund · InBC Investment · Amplitude Ventures | ↗ |
| SEEDEquity / VC | Nov 2023 | $0 | — | Amplitude Ventures · Myeloma Investment Fund | ↗ |
Growth signals
Latest recorded traffic for Reverb Therapeutics is 120 monthly website visits, down 69.2% over the last three months. Reverb Therapeutics's team grew 300% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Reverb Therapeutics in the Vancouver ecosystem
The Reverb Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Amplitude Ventures
Myeloma Investment Fund
KdT Ventures
InBC Investment
Seido Capital
Finchley Healthcare Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Reverb Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Reverb Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








